Latest News and Press Releases

Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key Findings Included Minimal Incidences of Dissociation or Cardiovascular...

MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company, pioneering the development of personalized...

MUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company pioneering the development of personalized...

MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized...

MUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized...

Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of Two Expected Closings of Round Increases Total Capital Raised to...

MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized...

MUNICH, Germany, June 23, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies...

Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy, safety, and tolerability of add-on treatment...

MUNICH, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global precision psychiatry biopharma company, pioneering the development of personalized therapies...